Search results for "Proton Pump Inhibitor"

showing 10 items of 43 documents

Exposure to Gastric Acid Inhibitors Increases the Risk of Infection in Preterm Very Low Birth Weight Infants but Concomitant Administration of Lactof…

2018

Objective: To investigate whether exposure to inhibitors of gastric acidity, such as H2 blockers or proton pump inhibitors, can independently increase the risk of infections in very low birth weight (VLBW) preterm infants in the neonatal intensive care unit. Study design: This is a secondary analysis of prospectively collected data from a multicenter, randomized controlled trial of bovine lactoferrin (BLF) supplementation (with or without the probiotic Lactobacillus rhamnosus GG) vs placebo in prevention of late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) in preterm infants. Inhibitors of gastric acidity were used at the recommended dosages/schedules based on the clinical judgmen…

ColonizationProton Pump InhibitorNeonatal intensive care unitAdministration OralHistamine H2 AntagonistProbioticGastroenterologyPediatricsH2 blocker0302 clinical medicineRisk FactorsInfant Very Low Birth Weight030212 general & internal medicineCandidaVLBW neonateLacticaseibacillus rhamnosusGestational agePerinatology and Child HealthHistamine H2 AntagonistsItalyNecrotizing enterocolitismedicine.symptomInfectionInfant PrematureHumanmedicine.medical_specialtyBirth weightGastric AcidSepsis03 medical and health sciencesEnterocolitis NecrotizingIntensive Care Units NeonatalSepsis030225 pediatricsInternal medicinemedicineH2 blockersHumansDietary Supplementbusiness.industryRisk FactorProbioticsInfant NewbornProton Pump Inhibitorsmedicine.diseaseLow birth weightLactoferrinConcomitantDietary SupplementsPediatrics Perinatology and Child HealthVLBW neonatesCandida; Colonization; H2 blockers; Infection; Lactoferrin; VLBW neonates; Pediatrics Perinatology and Child HealthGastric acidLactobacillus rhamnosubusinessNew Zealand
researchProduct

Uso degli inibitori di pompa protonica in un Policlinico Universitario

2012

Summary Introduction Proton pump inhibitors (PPIs) are highly prescribed drugs in Italy and in particular in the Sicilian region but little is known about their use in the hospital setting. Materials and methods PPI utilization and related costs were reviewed retrospectively by examining the pharmaceutical records of drug dispensation to the various wards of the Policlinico Universitario P. Giaccone of Palermo in 2010. Differences in the prescribing rates and drug preferences among the different clinical wards were analyzed. Results A total of 20,420 patients were hospitalized at the Policlinico of Palermo in 2010. Overall, the consumption of PPIs was 120 DDD/100 bed-days for the year 2010 …

Drug Utilizationmedicine.medical_specialtybusiness.industryHospital settingObesity SurgeryGeneral MedicinePrimary careProton pump inhibitorEsomeprazolePrescribing appropriateneSettore MED/02 - Storia Della MedicinaHospitalDrug utilizationSettore BIO/14 - FarmacologiaMedicineMedical prescriptionbusinessIntensive care medicineAdverse effectPrescribed drugsmedicine.drugDDD
researchProduct

Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

2006

Aims To compare information on drug–drug interactions (DDIs) reported on two standard drug-related information sources (Summary of Product Characteristics and Drugdex system by Micromedex), by assessing the prevalence and predictors of potential DDI with proton pump inhibitors (PPIs) in general practice. Methods From the ‘Caserta-1’ Local Health-Service database, 156 general practitioners (GPs) were recruited. From more than 180 000 individuals registered on their lists, we selected patients receiving co-prescription of PPI and medications at interaction risk, according to the Italian Summary of Product Characteristics (SPC) of PPI and Drugdex information, during the year 2003. Thereafter, …

DrugAdultMalemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectPharmacology toxicologyToxicologyDrugdexDrug PrescriptionsInternal medicineEpidemiologymedicineHumansPharmacology (medical)Drug InteractionsSummary of Product CharacteristicsRisk factorMedical prescriptiondrug information sourcesSummary of Product Characteristicsmedia_commonAgedgeneral practicePharmacologyAged 80 and overObserver VariationDrug pairbusiness.industryPharmacoepidemiologydrug information sources Drugdex drug–drug interaction general practice proton pump inhibitors Summary of Product CharacteristicsRegression analysisProton Pump InhibitorsDrug interactionMiddle Ageddrug information sources; Drugdex; drug-drug interaction; general practice; proton pump inhibitors; Summary of Product CharacteristicsSpontaneous reportingFamily medicineDrug Information ServicesInformation sourceFemalebusinessFamily Practicedrug-drug interactionBritish journal of clinical pharmacology
researchProduct

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Anti-helicobacter regimens

1996

Helicobacter pyloribiologybusiness.industryProton Pump InhibitorsGeneral Medicinebiology.organism_classificationAnti-Bacterial AgentsHelicobacter InfectionsHistamine H2 AntagonistsImmunologyHumansMedicineDrug Therapy CombinationHelicobacterbusinessThe Lancet
researchProduct

Editorial: proton pump inhibitor use in cirrhosis—a piece of the puzzle

2021

No abstract available

Liver CirrhosisCytochrome P-450 Enzyme SystemBreath TestsHumansProton Pump InhibitorsAminopyrine
researchProduct

Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply

2021

Liver CirrhosisMaleHepatologymedicine.drug_classbusiness.industryGastroenterologyProton-pump inhibitorProton Pump InhibitorsBone fracturemedicine.diseaseBioinformaticsFractures BonemedicineHumansPharmacology (medical)Point (geometry)businessAlimentary Pharmacology & Therapeutics
researchProduct

Proton Pump Inhibitors in Patients With Liver Cirrhosis: Evidence to Improve Their Battered Reputation.

2021

Liver Cirrhosismedicine.medical_specialtyCirrhosisHepatologybusiness.industryGastroenterologyMEDLINEProton Pump Inhibitorsmedicine.diseaseGastroenterologyRisk FactorsInternal medicinemedicineHumansIn patientbusinessThe American journal of gastroenterology
researchProduct

Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly

2011

Abstract Background Proton pump inhibitors (PPI) are among the most commonly prescribed medicines and their overuse is widespread in both primary and secondary care. Inappropriate prescription is of particular concern among elderly patients, who have often multiple comorbidities and need many drugs. Methods We evaluate the appropriateness of drugs for peptic ulcer or gastro-esophageal reflux disease (GERD) in a sample of elderly patients (65 years old or older) at admission and discharge in 38 internal medicine wards between January 2008 and December 2008, according to the presence of specific conditions or gastro-toxic drug combinations. Results Among 1155 patients eligible for the analysi…

MaleDrugmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectInappropriate PrescribingDiseaseappropriatenesselderly patientselderlyGastroenterologyCohort StudiesPharmacotherapyInternal medicineappropriateness; elderly; elderly patients; inappropriate prescription; proton pump inhibitorsPrevalenceInternal MedicinemedicineHumansMedical prescriptionpeptic ulcerAgedmedia_commonAged 80 and overSettore MED/12 - GastroenterologiaEvidence-Based Medicinebusiness.industrymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatrichedigestive system diseasesdrug therapy)inappropriate prescriptionConcomitantCohortGastroesophageal Refluxpeptic ulcer; drug therapy); Prevalence; hospitalization; elderlyGERDDrug Therapy CombinationFemaleGuideline Adherenceproton pump inhibitorsbusinessProton pump inhibitors Appropriateness ElderlyhospitalizationCohort studyEuropean Journal of Internal Medicine
researchProduct

The prognosis of patients having received optimal therapy for nonvariceal upper gastrointestinal bleeding might be worse in daily practice than in ra…

2010

International audience; BACKGROUND: Combination of endoscopic haemostatic and high-dose intravenous proton-pump inhibitors is considered to be the standard care for patients with acute peptic ulcer bleeding. AIM: This study assessed predictive factors of rebleeding and death in unselected patients presented to our hospital. METHODS: Consecutive patients with nonmalignant bleeding ulcers and stigmata of recent haemorrhage who received optimal treatment, between 22 August 2003 and 15 October 2007, were studied retrospectively. RESULTS: Among 140 included patients, 45 (32%) rebled and 30 received another haemostatic endoscopy, which was successful in 20 cases. In multivariate analysis, the onl…

MaleMultivariate analysisAdministration Oral2-Pyridinylmethylsulfinylbenzimidazoleslaw.inventionHospitals University0302 clinical medicineRandomized controlled trialRecurrenceRisk FactorslawOdds RatioHospital Mortality030212 general & internal medicineInfusions IntravenousPantoprazoleRandomized Controlled Trials as TopicAged 80 and overMortality rateHemostasis EndoscopicGastroenterologyMiddle AgedCombined Modality TherapyIntensive care unit3. Good healthIntensive Care UnitsPeptic Ulcer HemorrhageTreatment OutcomeInjections IntravenousFemale030211 gastroenterology & hepatologyFranceAdultmedicine.medical_specialtyRisk AssessmentYoung Adult03 medical and health sciencesInternal medicinemedicineHumansAgedRetrospective StudiesChi-Square DistributionHepatologybusiness.industryProton Pump Inhibitors[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyOdds ratiomedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyConfidence intervalSurgeryLogistic ModelsUpper gastrointestinal bleedingRockall scorebusiness
researchProduct